Lapatinib and Topotecan in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Did Not Respond to Cisplatin or Carboplatin

OBJECTIVES:

Primary

• Determine the efficacy of lapatinib ditosylate and topotecan hydrochloride, in terms of response, in patients with platinum-resistant or refractory ovarian epithelial or primary peritoneal cavity carcinoma.

Secondary

• Determine the overall survival time in patients treated with this regimen.
• Determine the time to progression in patients treated with this regimen.
• Assess the toxicity profile of this regimen in these patients.

Translational

• Determine the expression patterns of epidermal growth factor receptor, HER2/neu, hypoxia-induced factor 1 alpha, CD31, breast cancer resistance protein, and topoisomerase I by immunohistochemistry using tumor tissue from primary debulking surgery.
• Determine the feasibility of monitoring circulating tumor cells with specific biological markers to determine or follow response in these patients.

OUTLINE: This is a multicenter study.

Patients receive oral lapatinib ditosylate once daily on days 1-28 and topotecan hydrochloride IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Blood samples are collected at baseline and on day 8 of course 1 (immediately after the topotecan infusion) and are evaluated for pharmacological studies. Tumor tissue samples obtained at debulking surgery are examined by immunohistochemistry for epidermal growth factor receptor, HER1, ErbB1, HER2/neu, ErbB2, hypoxia-induced factor 1 alpha, CD31, platelet endothelial cell adhesion molecule 1, topoisomerase I, and breast cancer resistance protein.

After the completion of study treatment, patients are followed periodically for 2 years.

PROJECTED ACCRUAL: A total of 39 patients will be accrued for this study.

DISEASE CHARACTERISTICS:

• Histologically confirmed ovarian epithelial or primary peritoneal carcinoma
• Must have one of the following:

• Measurable disease
• Evaluable disease AND a CA-125 value that has increased ≥ 2 times the nadir value established after debulking surgery and first-line chemotherapy, confirmed by a second measurement within the past 21 days

• If a second measurement has not been done, it can be done ≥ 7 days but < 21 days prior to study treatment
• Platinum-refractory and/or -resistant disease after first-line chemotherapy

• Patients retreated with platinum agents (i.e., second relapse) are not eligible
• Patients treated with first-line triplet therapy (e.g., on clinical trial GOG-182) are eligible
• Must have had debulking surgery

• Tissue blocks from this surgery must be available
• No CNS metastases

PATIENT CHARACTERISTICS:

• Eastern Cooperative Oncology Group (ECOG) performance status 0-2
• Life expectancy ≥ 12 weeks
• Absolute neutrophil count ≥ 1,500/mm³
• Platelet count ≥ 100,000/mm³
• Bilirubin ≤ 1.5 times upper limit of normal (ULN)
• AST ≤ 3 times ULN (5 times ULN if there is liver involvement)
• Creatinine ≤ 1.5 times ULN
• Hemoglobin ≥ 9.0 g/dL
• No uncontrolled infection
• No New York Heart Association class III or IV heart failure
• Left Ventricular Ejection Fraction (LVEF) ≥ 50% by echocardiogram
• No seizure disorder
• No other prior or concurrent malignancy in the past 5 years except nonmelanoma skin cancer or carcinoma in situ of the cervix
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics
• No prior topotecan hydrochloride
• More than 4 weeks since prior surgery or procedure involving the peritoneum or pleura

• CA125 measurements used as basis for enrollment must be made outside of this 4-week window
• More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C) and recovered
• More than 4 weeks since prior immunotherapy
• More than 4 weeks since prior biologic therapy
• More than 4 weeks since prior radiotherapy
• No prior radiotherapy to > 25 % of bone marrow
• No prior therapy with an anti-epidermal growth factor receptor or anti-HER2 tyrosine kinase inhibitors
• No prior agents targeting topoisomerase I
• No prior or concurrent human anti-mouse antibodies (HAMA) in patients with non-measurable disease
• At least 14 days since prior and no concurrent herbal or dietary supplements

• Vitamin supplements are allowed unless they include herbal additives
• At least 14 days since prior and no concurrent CYP3A4 inducers, including any of the following:

• Rifampin
• Rifabutin
• Rifapentine
• Phenytoin
• Carbamazepine
• Phenobarbital
• Efavirenz
• Nevirapine
• Cortisone (> 50 mg)
• Hydrocortisone (> 40 mg)
• Prednisone (> 10 mg)
• Methylprednisolone (> 8 mg)
• Dexamethasone (> 1.5 mg)

• Oral doses of ≤ 1.6 mg of dexamethasone allowed
• Modafinil
• Hypericum perforatum (St. John's wort)
• At least 7 days since prior and no concurrent CYP3A4 inhibitors, including any of the following:

• Clarithromycin
• Erythromycin
• Troleandomycin
• Itraconazole
• Ketoconazole
• Fluconazole (> 150 mg daily)
• Voriconazole
• Delaviridine
• Nelfinavir
• Amprenavir
• Ritonavir
• Indinavir
• Saquinavir
• Lopinavir
• Verapamil
• Diltiazem
• Nefazodone
• Fluvoxamine
• Cimetidine
• Aprepitant
• Grapefruit or grapefruit juice
• At least 6 months since prior and no concurrent amiodarone
• No concurrent participation in another study involving a pharmacologic agent (e.g., drugs, biologics, immunotherapy, gene therapy) for symptom control or therapeutic intent